Source: International Congress 2019 – Interstitial lung disease registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Lewandowska (Warsaw, Poland), P. Radwan-Rohrenschef (Warsaw, Poland), M. Sobiecka (Warsaw, Poland), M. Bartosiewicz (Warsaw, Poland), I. Siemion-Szczesniak (Warsaw, Poland), S. Wesolowski (Warsaw, Poland), I. Bestry (Warsaw, Poland), A. Gladzka (Warsaw, Poland), D. Klatka (Warsaw, Poland), J. Kus (Warsaw, Poland). Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland.. 4716

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Real-life experience with pirfenidone in idiopathic pulmonary fibrosis (IPF) in a single centre in Italy. A retrospective study. Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Central European idiopathic pulmonary fibrosis (IPF) patients survey Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF) Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Body composition and mortality in idiopathic pulmonary fibrosis (IPF): a prospective cohort study. Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation Year: 2018 Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Lung function of idiopathic pulmonary fibrosis: Russian IPF registry (Moscow region) Source: International Congress 2019 – Respiratory function assessment in disease Year: 2019 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early single centre Irish experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Clinical pattern of idiopathic pulmonary fibrosis in Iran: A retrospective study Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021 Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients? Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012